Evidence map›Paper›PMID 34168400›Full record

ReviewWorld journal of gastroenterology2021

Interplay between nuclear factor erythroid 2-related factor 2 and inflammatory mediators in COVID-19-related liver injury.

Dan-Dan Zhu, Xue-Mei Tan, Li-Qing Lu, Si-Jia Yu, Ru-Li Jian, Xin-Fang Liang, Yi-Xuan Liao, Wei Fan, Lucíia Barbier-Torres, Austin Yang and 2 more

Open access · hybridAbstract readReview
In one paragraph

Review in World journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. COVID-19: a multi-organ perspective.Frontiers in cellular and infection microbiology · 2024
    Review
  2. Review
  3. Liver injury in COVID-19: A minireview.World journal of gastroenterology · 2022
    Review
  4. Fenofibrate for COVID-19 and related complications as an approach to improve treatment outcomes: the missed key for Holy Grail.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Dan-Dan ZhuDepartment of Gastroenterology, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China.
Xue-Mei TanDepartment of Gastroenterology, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China.
Li-Qing LuKey Laboratory of Cancer proteomics of Chinese Ministry of Health, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China.
Si-Jia YuDepartment of Gastroenterology, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China.
Ru-Li JianDepartment of Gastroenterology, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China.
Xin-Fang LiangDepartment of Gastroenterology, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China.
Yi-Xuan LiaoDepartment of Gastroenterology, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China.
Wei FanDepartment of Medicine, Division of Digestive and Liver Diseases, Cedars-Sinai Medical Center, Los Angeles, CA 90048, United States.
Lucíia Barbier-TorresDepartment of Medicine, Division of Digestive and Liver Diseases, Cedars-Sinai Medical Center, Los Angeles, CA 90048, United States.
Austin YangDepartment of Biology, East Los Angeles College, Los Angeles, CA 91008, United States.
He-Ping YangDepartment of Medicine, Division of Digestive and Liver Diseases, Cedars-Sinai Medical Center, Los Angeles, CA 90048, United States.
Ting LiuDepartment of Gastroenterology, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China. liuting818@126.com.
Central South University · CNXiangya Hospital Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 is a global pandemic and poses a major threat to human health worldwide. In addition to respiratory symptoms, COVID-19 is usually accompanied by systemic inflammation and liver damage in moderate and severe cases. Nuclear factor erythroid 2-related factor 2 (NRF2) is a transcription factor that regulates the expression of antioxidant proteins, participating in COVID-19-mediated inflammation and liver injury. Here, we show the novel reciprocal regulation between NRF2 and inflammatory mediators associated with COVID-19-related liver injury. Additionally, we describe some mechanisms and treatment strategies.

Indexed as

COVID-19Inflammation MediatorsNF-E2-Related Factor 2HumansLiverLiver DiseasesOxidative StressSARS-CoV-2Signal TransductionInflammation MediatorsNF-E2-Related Factor 2COVID-19-related liver injuryInflammatory mediatorNuclear factor erythroid 2-related factor 2Oxidative stressTherapeutic targets

Identifiers

PMID34168400
PMCPMC8192291
OpenAlexW3173104516

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.